Skip to main content
Top
Published in: Journal of General Internal Medicine 2/2016

01-02-2016 | Editorial

Academic–Industry Research Partnerships: an Emerging Opportunity or Just Smoke and Mirrors?

Authors: Michael Hochman, MD, MPH, Rachael Bedard, MD

Published in: Journal of General Internal Medicine | Issue 2/2016

Login to get access

Excerpt

It is a time of famine for clinical research, and academic investigators have had to hunt for viable funding sources. While inflation-adjusted public funding for biomedical research has declined over the past two decades, private industry’s share of the funding pie has increased by 13 %.1 The pharmaceutical industry has historically been eager to partner with academic investigators both to tap the academic talent pool and to enhance the credibility of its conclusions. In this month’s issue of the JGIM, Tierney et al. consider situations in which academic–industry partnerships might be both ethical and mutually beneficial.2
Literature
1.
go back to reference Moses H 3rd, Matheson DH, Cairns-Smith S, George BP, Palisch C, Dorsey ER. The anatomy of medical research: US and international comparisons. JAMA. 2015;313(2):174–89.CrossRefPubMed Moses H 3rd, Matheson DH, Cairns-Smith S, George BP, Palisch C, Dorsey ER. The anatomy of medical research: US and international comparisons. JAMA. 2015;313(2):174–89.CrossRefPubMed
2.
3.
go back to reference Bodenheimer T. Uneasy alliance – clinical investigators and pharmaceutical industry. N Engl J Med. 2000;342:1539–1544.CrossRefPubMed Bodenheimer T. Uneasy alliance – clinical investigators and pharmaceutical industry. N Engl J Med. 2000;342:1539–1544.CrossRefPubMed
4.
go back to reference Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR, TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–42.CrossRefPubMed Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR, TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–42.CrossRefPubMed
6.
go back to reference Kroenke K, West SL, Swindle R, et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA. 2001;286:2947–2955.CrossRefPubMed Kroenke K, West SL, Swindle R, et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA. 2001;286:2947–2955.CrossRefPubMed
7.
go back to reference American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Am J Psychiatry, vol. 167(supplement)(10). 3rd ed. 2010:1. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Am J Psychiatry, vol. 167(supplement)(10). 3rd ed. 2010:1.
Metadata
Title
Academic–Industry Research Partnerships: an Emerging Opportunity or Just Smoke and Mirrors?
Authors
Michael Hochman, MD, MPH
Rachael Bedard, MD
Publication date
01-02-2016
Publisher
Springer US
Published in
Journal of General Internal Medicine / Issue 2/2016
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-015-3527-8

Other articles of this Issue 2/2016

Journal of General Internal Medicine 2/2016 Go to the issue

Clinical Practice: Clinical Images

Hypertriglyceridemia-Induced Pancreatitis

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine